// App-Quantinova.ai

THU0396 : IMPACT OF IXEKIZUMAB ON WORK PRODUCTIVITY IN PATIENTS WITH ANKYLOSING SPONDYLITIS: RESULTS FROM THE COAST-V AND COAST-W TRIALS AT 52 WEEKS

Researchers

Presenter

  • H. Marzo-Ortega

Principal Investigators

  • P. J. Mease

  • P. Rahman

  • V. Navarro-Compn

  • V. Strand

  • M. Dougados

  • B. Combe

  • J. C. C. Wei

  • X. Baraliakos

  • T. Hunter

  • D. Sandoval

  • X. LI

  • B. Zhu

  • L. Bessette

  • A. Deodhar

Medical Centers

  • University of Leeds, West Yorkshire, United Kingdom

  • Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA

  • Memorial University of Newfoundland, St. John's, NF, Canada

  • Hospital Universitario La Paz, Madrid, Spain

  • Stanford University Medical Center, Stanford, California, United States

  • Bichat Hospital, Paris, France

  • CHU Montpellier, Montpellier University, Montpellier, France

  • Chung Shan Medical University, Taichung City, Taiwan (Republic of China)

  • St. Elisabeth Group, GmbH, Herne, Germany

  • Eli Lilly and Company, Indianapolis, United States of America

  • Laval University and CHU de Quebec Research Centre, Quebec City, Canada

  • Oregon Health & Science University, Portland, United States of America

Locations

  • United Kingdom

  • United States

  • Canada

  • Spain

  • France

  • Republic of South Korea

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Autoimmune (AI)

Disease

  • Ankylosing spondylitis

  • Spondyloarthritis

Biomarkers

  • N/A

Drug/Treatment

  • Adalimumab

  • LY2439821

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • NCT02696785

  • NCT02696798

Sponsors

  • Janssen Pharmaceutical

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved